<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947153</url>
  </required_header>
  <id_info>
    <org_study_id>1288.21</org_study_id>
    <nct_id>NCT01947153</nct_id>
  </id_info>
  <brief_title>Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.</brief_title>
  <official_title>Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto® (Two Fixed Dose Combination Tablets of Linagliptin 2.5 mg and Metformin 500 mg) Compared With the Free Combination of Linagliptin 5 mg and Metformin 1000 mg Tablets Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to demonstrate bioequivalence of two 2.5 mg
      linagliptin/500 mg metformin fixed dose combination tablets compared to the free combination
      of the linagliptin 5 mg and metformin 1000 mg in healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours)</measure>
    <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Linagliptin:
AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</measure>
    <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Metformin:
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)</measure>
    <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Linagliptin:
Cmax (maximum measured concentration of the analyte in plasma)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)</measure>
    <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Metformin:
Cmax (maximum measured concentration of the analyte in plasma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</measure>
    <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Linagliptin:
AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</measure>
    <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Metformin:
AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: AUC 0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</measure>
    <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Linagliptin:
AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fixed dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin/Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin and Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Free combination</description>
    <arm_group_label>Free combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Fixed dose combination</description>
    <arm_group_label>Fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Combination</description>
    <arm_group_label>Fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Free combination</description>
    <arm_group_label>Free combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation

          -  Healthy males and females according to the following criteria:

        Based upon a complete medical history, including physical examination, vital signs (BP,
        PR), 12-lead ECG and clinical laboratory tests (haematology, clinical chemistry and
        urinalysis).

          -  Age 18 to 45 years (incl.)

          -  Body mass index by Quetelet between 18.50 to 24.99 kg/m2 (incl.)

          -  Female subjects of childbearing potential who agree on using double-barrier
             contraception during the study. If a female is postmenopausal (no menses for at least
             2 years) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy) she will be exempt from the requirement. In case of using oral
             contraceptives, these should be withdrawn at least 2 months before the first drug
             dosing.

          -  Male subjects who agree on using effective contraception during the study (barrier
             contraceptive methods)

        Exclusion criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Positive results of blood tests for infections (HIV, syphilis, hepatitis B or C)

          -  A positive urine drug screening test at screening and on admission to the trial site
             in each treatment period.

          -  A positive alcohol breath test at screening and on admission to the trial site in each
             treatment period.

          -  Surgery of the gastrointestinal tract (except appendectomy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1288.21.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>September 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <results_first_submitted>January 27, 2015</results_first_submitted>
  <results_first_submitted_qc>February 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2015</results_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fixed Dose Combination First, Then Free Combination</title>
          <description>5 mg linagliptin / 1000mg metformin given as two 2.5mg linagliptin / 500mg metformin fixed dose combination (FDC) tablets first; then free combination: one 5mg linagliptin tablet and one 1000mg metformin tablet</description>
        </group>
        <group group_id="P2">
          <title>Free Combination First, Then Fixed Dose Combination</title>
          <description>Free combination: one 5mg linagliptin tablet and one 1000mg metformin tablet first; then 5 mg linagliptin / 1000mg metformin given as two 2.5mg linagliptin / 500mg metformin fixed dose combination (FDC) tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Test Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Test Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): includes all subjects who had been dispensed study medication and were documented to have taken at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects treated with 5 mg linagliptin / 1000 mg metformin as fixed dose combination or as free dose combination.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours)</title>
        <description>Linagliptin:
AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours)</description>
        <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>subject set for the evaluation of pharmacokinetic endpoints of linagliptin (PKS-L): includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination</title>
            <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
          </group>
          <group group_id="O2">
            <title>Free Combination</title>
            <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours)</title>
          <description>Linagliptin:
AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours)</description>
          <population>subject set for the evaluation of pharmacokinetic endpoints of linagliptin (PKS-L): includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293" spread="23.4"/>
                    <measurement group_id="O2" value="288" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.027</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.370</ci_lower_limit>
            <ci_upper_limit>107.688</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
        <description>Metformin:
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</description>
        <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>The subject set for the evaluation of pharmacokinetic endpoints of metformin (PKS-M): includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for metformin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination</title>
            <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
          </group>
          <group group_id="O2">
            <title>Free Combination</title>
            <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
          <description>Metformin:
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</description>
          <population>The subject set for the evaluation of pharmacokinetic endpoints of metformin (PKS-M): includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for metformin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of metformin</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13000" spread="27.3"/>
                    <measurement group_id="O2" value="12100" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>105.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.032</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.645</ci_lower_limit>
            <ci_upper_limit>110.941</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)</title>
        <description>Linagliptin:
Cmax (maximum measured concentration of the analyte in plasma)</description>
        <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS-L: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination</title>
            <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
          </group>
          <group group_id="O2">
            <title>Free Combination</title>
            <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)</title>
          <description>Linagliptin:
Cmax (maximum measured concentration of the analyte in plasma)</description>
          <population>PKS-L: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="36.4"/>
                    <measurement group_id="O2" value="9.57" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>0.0014</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>109.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.063</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.299</ci_lower_limit>
            <ci_upper_limit>120.968</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)</title>
        <description>Metformin:
Cmax (maximum measured concentration of the analyte in plasma)</description>
        <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS-M: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for metformin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination</title>
            <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
          </group>
          <group group_id="O2">
            <title>Free Combination</title>
            <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)</title>
          <description>Metformin:
Cmax (maximum measured concentration of the analyte in plasma)</description>
          <population>PKS-M: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for metformin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of metformin</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1840" spread="28.2"/>
                    <measurement group_id="O2" value="1700" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>105.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.043</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.471</ci_lower_limit>
            <ci_upper_limit>113.692</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
        <description>Linagliptin:
AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</description>
        <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS-L: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination</title>
            <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
          </group>
          <group group_id="O2">
            <title>Free Combination</title>
            <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
          <description>Linagliptin:
AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</description>
          <population>PKS-L: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467" spread="25.8"/>
                    <measurement group_id="O2" value="479" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.040</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.177</ci_lower_limit>
            <ci_upper_limit>105.208</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
        <description>Metformin:
AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</description>
        <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS-M: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for metformin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of metformin</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination</title>
            <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
          </group>
          <group group_id="O2">
            <title>Free Combination</title>
            <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
          <description>Metformin:
AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</description>
          <population>PKS-M: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for metformin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of metformin</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13400" spread="26.8"/>
                    <measurement group_id="O2" value="12500" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.031</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.274</ci_lower_limit>
            <ci_upper_limit>110.254</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: AUC 0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
        <description>Linagliptin:
AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</description>
        <time_frame>2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS-L: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose Combination</title>
            <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
          </group>
          <group group_id="O2">
            <title>Free Combination</title>
            <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: AUC 0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
          <description>Linagliptin:
AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</description>
          <population>PKS-L: includes all subjects of the TS who provided at least 1 observation for at least 1 primary endpoint for linagliptin and had no important protocol violations with respect to the statistical evaluation of pharmacokinetic endpoints of linagliptin</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293" spread="23.4"/>
                    <measurement group_id="O2" value="288" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value relates to the null hypothesis of non-equivalence.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.027</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.370</ci_lower_limit>
            <ci_upper_limit>107.688</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first study drug administration until 30±2 days after the last study drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fixed Dose Combination</title>
          <description>Linagliptin/Metformin
Linagliptin: Fixed dose combination: 2x 2.5mg Metformin: Combination: 500mg</description>
        </group>
        <group group_id="E2">
          <title>Free Combination</title>
          <description>Linagliptin and Metformin
Metformin: Free combination 5mg Linagliptin: Free combination 1000mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

